By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Elixir Pharmaceuticals 

One Kendall Square
Building 1000, Fifth Floor
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-995-7000 Fax: 617-995-7050


Company News
Elixir Pharmaceuticals Signs Option Agreement with a Major Pharmaceutical Company, Novartis Corporation (NVS); Deal Could Exceed $500 Million, Completes $12M Equity Financing 5/19/2009 11:42:15 AM
Elixir Pharmaceuticals' Phase III Trial of Metformin-Mitiglinide Combination Therapy Demonstrates Significant Reductions in HbA1c (Blood Glucose) Levels Compared to Type 2 Diabetes Patients Not Well-Controlled on Metformin Alone 11/19/2008 8:58:40 AM
Elixir Pharmaceuticals to Present at the UBS Warburg Global Life Sciences Conference 9/18/2008 8:44:13 AM
Elixir Pharmaceuticals Announces Exclusive Sirtuin Intellectual Property License Agreement with Boston University School of Medicine 7/1/2008 11:36:32 AM
Elixir Pharmaceuticals Announces Ghrelin Agonist Data Presentation at the Endocrine Society Annual Meeting 6/18/2008 10:12:19 AM
Elixir Pharmaceuticals Announces New Data at the 2008 American Diabetes Association Annual Meeting 6/9/2008 10:32:56 AM
Elixir Pharmaceuticals Researchers Publish New Data Validating Ghrelin as a Key Metabolic Regulator 5/28/2008 8:48:45 AM
Elixir Pharmaceuticals Announces Issuance of SIRT Patent Covering Development of New Therapies Based on Breakthrough Science 4/28/2008 8:51:02 AM
Elixir Pharmaceuticals Establishes National Diabetes Advisory Board 4/9/2008 9:08:32 AM
Elixir Pharmaceuticals Presents New Data on Ghrelin Inhibition at Keystone Meeting 2/22/2008 8:40:50 AM